Related Experiment Video
Updated: Jan 16, 2026
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Development of Novel PTPN2/1 Inhibitors for the Treatment of Melanoma
Dawei Wang1,2, Mingge Song1,2, Chen Tong1,3
1State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
The global incidence of melanoma has risen substantially over the past two decades, driving an urgent need for novel therapeutic strategies. The nonreceptor protein tyrosine phosphatases PTPN2/PTPN1 have emerged as promising therapeutic targets, yet developing effective inhibitors faces significant drug-like property challenges. Through rational drug design, we discovered WS35─a potent dual PTPN2/1 inhibitor exhibiting exceptional enzymatic activity (PTPN2 IC50 = 5.8 nM, PTPN1 IC50 = 12.8 nM), favorable safety profiles, and enhanced oral bioavailability (F = 7.1%). Mechanistic studies demonstrate that WS35 modulates the IFNγ-JAK-STAT signaling axis, significantly augmenting CD8+ T-cell tumor infiltration. In B16-OVA syngeneic models, WS35 monotherapy and its combination with an anti-PD-1 antibody achieved robust tumor growth suppression, outperforming AC484, with no observable systemic toxicity. Collectively, WS35 represents a preclinical candidate with validated efficacy and safety for developing novel antimelanoma therapeutics.
Insights
A new drug, WS35, effectively targets melanoma by inhibiting PTPN2/1 phosphatases. It enhances anti-tumor immunity and shows promise as a safe, orally available melanoma treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma incidence is rising globally, necessitating new treatments.
- PTPN2 and PTPN1 phosphatases are key targets for melanoma therapy.
- Developing effective inhibitors with good drug-like properties is challenging.
Purpose of the Study:
- To discover and characterize WS35, a novel dual PTPN2/PTPN1 inhibitor.
- To evaluate the therapeutic potential of WS35 in melanoma models.
- To assess the safety and pharmacokinetic profile of WS35.
Main Methods:
- Rational drug design was employed to discover WS35.
- Enzymatic activity was assessed using IC50 values (PTPN2 = 5.8 nM, PTPN1 = 12.8 nM).
- Mechanistic studies involved analyzing the IFNγ-JAK-STAT pathway and CD8+ T-cell infiltration. In vivo efficacy was tested in B16-OVA syngeneic models, comparing WS35 monotherapy and combination therapy with anti-PD-1 to AC484.
Main Results:
- WS35 demonstrated potent dual inhibition of PTPN2/1 with favorable safety and oral bioavailability (F=7.1%).
- WS35 modulated the IFNγ-JAK-STAT axis, increasing CD8+ T-cell infiltration into tumors.
- WS35 monotherapy and combination therapy significantly suppressed tumor growth in B16-OVA models, outperforming AC484 with no observed toxicity.
Conclusions:
- WS35 is a potent dual PTPN2/1 inhibitor with validated preclinical efficacy and safety.
- WS35 enhances anti-tumor immunity by modulating the IFNγ-JAK-STAT pathway and promoting T-cell infiltration.
- WS35 represents a promising preclinical candidate for novel melanoma therapeutics.
